| 罗卫,汪如镜,蒋红宇,刘梦辉.衢州雷氏益髓降火方联合重组人生长激素治疗女童青春期矮小症的临床疗效研究[J].浙江中西医结合杂志,2026,36(1): |
| 衢州雷氏益髓降火方联合重组人生长激素治疗女童青春期矮小症的临床疗效研究 |
| Clinical efficacy study of Quzhou Lei"s marrow and fire reduction formula combined with recombinant human growth hormone in the treatment of girls with short stature entering puberty |
| 投稿时间：2024-12-22 修订日期：2025-10-07 |
| DOI： |
| 中文关键词: 青春期矮小症 衢州雷氏益髓降火方 重组人生长激素 女童 |
| 英文关键词:short stature entering puberty Quzhou Lei"s marrow and fire reduction formula recombinant human growth hormone girls |
| 基金项目:浙江省中医药科技计划项目(2024ZL1211) |
|
| 摘要点击次数: 5 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的 探讨对青春期矮小女童采用衢州雷氏益髓降火方联合重组人生长激素治疗的效果。方法 选择2023年2月-2024年2月我院就诊且诊断符合中医证型为“阴虚火旺型”的青春期矮小症的女性患儿60例,按照随机数表法分为对照组、试验组各30例,其中对照组采用重组人生长激素(recombinant human growth hormone,rhGH)治疗,试验组在对照组的基础上加用衢州雷氏益髓降火方治疗,疗程均为9个月。比较2组患儿治疗前后的生长速率(growth velocity,GV)、预测成年身高(predicts adult height,PAH)、骨成熟度、子宫卵巢容积、胰岛素样生长因子-1(insulin-like growth factor-1,IGF-1)、类胰岛素样生长因子结合蛋白-3(insulin-like growth factor-binding protein-3,IGFBP-3)、促甲状腺激素(thyroid stimulating hormone,TSH)、游离甲状腺素(free thyroxine-4,FT4)及不良反应发生率。结果:治疗前,两组患儿基线资料、GV、PAH、骨成熟度、子宫卵巢容积、IGF-1、IGFBP-3、TSH、FT4水平比较差异均无统计学意义(P＞0.05)。治疗后,两组患儿GV、PAH、骨成熟度、IGF-1、IGFBP-3水平较治疗前均升高(P＜0.05),TSH、FT4水平与治疗前比较无明显差异(P＞0.05),对照组子宫卵巢容积与治疗前比较无明显差异(P＞0.05),试验组子宫卵巢容积较治疗前缩小(P＜0.05),试验组患儿PAH高于对照组(P＜0.05),骨成熟度、子宫卵巢容积低于对照组(P＜0.05),组间GV、IGF-1、IGFBP-3、TSH、FT4水平比较均无明显差异(P＞0.05),两组患儿不良反应发生率比较,差异无统计学意义(P＞0.05)。结论:衢州雷氏益髓降火方联合重组人生长激素治疗女童青春期矮小症疗效确切,可改善患儿预测成年身高,延缓骨龄进展,控制第二性征,且用药安全性高。 |
| 英文摘要: |
| Objective To investigate the effect of Quzhou Lei"s marrow and fire reduction formula combined with recombinant human growth hormone in girls with short stature entering puberty. Methods A total of 60 children with female short stature entering puberty with the TCM syndrome type of "yin deficiency and fire prosperity type" from February 2023 to February 2024 were divided into the control group and the experimental group (30 cases in each group) according to the random number table method, of which the control group was treated with recombinant human growth hormone (rhGH), and the experimental group was treated with Quzhou Lei"s marrow and fire reduction formula on the basis of the control group, and the treatment period was 9 months. The growth velocity (GV), predicted adult height (PAH), bone maturity, utero-ovarian volume, insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein-3 (IGFBP-3), thyroid stimulating hormone (TSH), free thyroxine-4 (FT4) and the incidence of adverse reactions were compared between the two groups before and after treatment. Results Before treatment, there were no significant differences in the levels of baseline datas, GV, PAH, bone maturity, utero-ovarian volume, IGF-1, IGFBP-3, TSH and FT4 between the two groups (P>0.05). After treatment, the levels of GV, PAH, bone maturity, IGF-1 and IGFBP-3 in the two groups were higher than those before treatment (P<0.05), and there was no significant difference in the levels of TSH and FT4 before treatment (P>0.05), and there was no significant difference in uterine and ovarian volume in the control group compared with that before treatment (P>0.05), and the utero-ovarian volume in the experimental group was reduced compared with that before treatment (P<0.05). The PAH of the experimental group were higher than those of the control group (P<0.05), the bone maturity and uterus-ovarian volume were lower than those of the control group (P<0.05), and there were no significant differences in the levels of GV, IGF-1, IGFBP-3, TSH and FT4 between the groups (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Quzhou Lei"s marrow and fire reduction formula combined with recombinant human growth hormone has a definite effect in the treatment of girls with short stature entering puberty, which can improve the predicted adult height of children, delay the progression of bone age, control secondary sexual characteristics, and have a high drug safety. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
